logo

Intersect Ent Inc (XENT)



Trade XENT now with
  Date
  Headline
8/2/2017 12:41:31 PM Wedbush Is Lowering Intersect ENT Inc (XENT) 2018 Rev. Estimate To 111.6 M From 112.0 M
8/2/2017 12:41:10 PM Wedbush Is Raising Intersect ENT Inc (XENT) 2017 Rev. Estimate To 93.5 M From 91.1 M
8/2/2017 12:40:36 PM Wedbush Is Increasing Intersect ENT Inc (XENT) Q4 17 Rev. Estimate To 27.8 M From 27.7 M
8/2/2017 12:40:13 PM Wedbush Is Increasing Intersect ENT Inc (XENT) Q3 17 Rev. Estimate To 21.3 M From 20.4 M
8/2/2017 12:39:47 PM Wedbush Is Increasing Intersect ENT Inc (XENT) 2017 Estimate To -0.63 From -0.72
8/2/2017 12:39:24 PM Wedbush Is Cutting Intersect ENT Inc (XENT) Q3 17 Estimate To -0.26 From -0.24
7/20/2017 4:12:06 PM Intersect ENT Appoints Teresa Kline To Board Of Directors
5/22/2017 7:06:44 AM Intersect ENT Announces PDUFA Date As Jan.7, 2018 For Office-Based SINUVA Steroid Releasing Sinus Implant
5/3/2017 8:42:59 AM Wedbush Is Cutting Intersect ENT Inc (XENT) 2018 Estimate To -0.37 From -0.36
5/3/2017 8:42:47 AM Wedbush Is Raising Intersect ENT Inc (XENT) 2017 Estimate To -0.72 From -0.74
5/3/2017 8:42:24 AM Wedbush Is Raising Intersect ENT Inc (XENT) 2018 Rev. Estimate To 112.0 M From 108.8 M
5/3/2017 8:42:12 AM Wedbush Is Increasing Intersect ENT Inc (XENT) 2017 Rev. Estimate To 91.1 M From 88.5 M
3/8/2017 8:02:31 AM Intersect ENT Submits NDA To FDA For Office-Based RESOLVE Steroid Releasing Implant For Recurrent Chronic Sinus Disease
3/1/2017 6:35:00 AM Wedbush Reiterates Intersect ENT Inc (XENT) At Outperform With $25 Price Target
2/24/2017 12:31:53 PM Wedbush Reiterates Intersect ENT Inc (XENT) At Outperform With $25 Price Target
2/24/2017 8:04:39 AM Intersect ENT Unveils FDA Approval Of PROPEL Contour, For Use In Treating Frontal And Maxillary Sinuses